Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

NCT00887575

Last updated date
Study Location
Holy Cross Hospital
Ft. Lauderdale, Florida, 33308, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Female patients, age ≥18 years

2. Histologically confirmed invasive ER-, PR-, and HER2-negative (triple-negative) adenocarcinoma of the breast

3. Triple-negative tumors are defined as:

- For HER2-negative:

- Fluorescence in situ hybridization (FISH)-negative (defined by ratio <2.2) OR

- Immunohistochemical (IHC) 0, IHC 1+, OR

- IHC 2+ or IHC 3+ and FISH-negative (defined by ratio <2.2)

- For ER- and PR-negative: <10% tumor staining by immunohistochemistry (IHC)

4. Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). T1N0M0 lesions are excluded. Patients with metastatic disease are excluded.

5. Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. Patients with lesions measurable only by imaging will require repeat imaging after 3 cycles and prior to surgery

6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2

7. Neuropathy grade <1 by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0)

8. Resolution of all acute effects of surgical procedures to grade ≤1.

For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound is required

9. Adequate hematologic function with:

- Absolute neutrophil count (ANC) >1500/μL

- Platelets ≥100,000/μL

- Hemoglobin ≥10 g/dL

10. Adequate hepatic and renal function with:

- Serum bilirubin ≤ the institutional upper limit of normal (ULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x institutional ULN

- Alkaline phosphatase ≤2.5 x institutional ULN

- Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥40 mL/min

11. Left ventricular ejection fraction (LVEF) ≥50% by multigated acquisition (MUGA) or echocardiogram (ECHO)

12. Bilateral, synchronous breast cancer is allowed if one primary tumor meets the inclusion criteria

13. Knowledge of the investigational nature of the study and ability to provide consent for study participation

14. Ability and willingness to comply with study visits, treatment, testing, and other study procedures

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Previous treatment for this breast cancer


2. Previous treatment with paclitaxel or carboplatin


3. Previous treatment with sunitinib or other angiogenic inhibitors (including, but not
limited to bevacizumab, sorafenib, thalidomide)


4. Any of the following within the 12 months prior to starting study treatment:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, congestive heart failure, cerebrovascular accident including transient ischemic
attack, or pulmonary embolus


5. Uncontrolled hypertension (blood pressure >150/100 mmHg despite optimal medical
therapy)


6. Ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade, or
prolongation of the QTc interval to >470 msec


7. Major surgery, significant traumatic injury, or radiation therapy within 4 weeks of
starting study treatment. An interval of at least 1week is required following minor
surgical procedures, with the exception of placement of a vascular access device


8. Grade 3 hemorrhage within 4 weeks of starting study treatment


9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication


10. Known human immunodeficiency virus (HIV) infection or other serious infection


11. Concomitant treatment with drugs having proarrhythmic potential including terfenadine,
quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol,
risperidone, indapamide, and flecainide


12. Concurrent use of the potent CYP3A4 inhibitors ketoconazole, itraconazole,
clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir,
amprenavir, indinavir, nelfinavir, delavirdine and voriconazole and CYP3A4 inducers
rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's
Wort, and dexamethasone. Use of dexamethasone for study premedication is allowed.
Grapefruit and grapefruit juice is prohibited. Alternative therapies should be used
when available. If use of a potent CYP3A4 inhibitor or inducer is necessary, this must
be approved by the Study Chair


13. Known or suspected hypersensitivity to drugs containing Cremophor®EL (polyoxyethylated
castor oil) such as cyclosporine or teniposide


14. Pregnancy or breast-feeding. Negative serum pregnancy test is required within 7 days
prior to first study treatment (Day 1, Cycle ) for all women of childbearing
potential. Patients of childbearing potential must agree to use a birth control method
that is approved by their study physician while receiving study treatment and for
three months after the last dose of study treatment. Patients must agree to not
breast-feed while receiving study treatment


15. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal
agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator
(SERM). Patients must have discontinued use of such agents prior to beginning study
treatment


16. History of malignancy treated with curative intent within the previous 5 years with
the exception of skin cancer, cervical carcinoma in situ, or follicular thyroid
cancer. Patients with previous invasive cancers (including breast cancer) are eligible
if the treatment was completed more than 5 years prior to initiating current study
treatment, and there is no evidence of recurrent disease


17. Use of any investigational agent within 30 days of administration of the first dose of
study drug or concurrent treatment on another clinical study


18. Requirement for radiation therapy concurrent with study anticancer treatment. Patients
who require breast or chest wall radiation therapy after surgery are eligible, but
will have maintenance sunitinib interrupted while receiving radiation


19. Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from a
physical examination or clinical laboratory test result that would cause reasonable
suspicion of a disease or condition, that contraindicates the use of study drugs, that
may increase the risk associated with study participation, that may affect the
interpretation of the results, or that would make the patient inappropriate for this
study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast CancerNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT03573648
  1. Washington, District of Columbia
  2. Baltimore, Maryland
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Breast CancerNeoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -
NCT03819010
  1. Badalona, Barcelona
  2. Madrid,
  3. Valencia,
  4. Oporto,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Official Title  ICMJE Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer
Brief Summary This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.
Detailed Description This open label, Phase I/II trial is designed to evaluate the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer. The Phase I portion of this study will determine the maximum tolerated dose (MTD) of paclitaxel, sunitinib and carboplatin that can be used together as neoadjuvant treatment in patients with locally advanced breast cancer. The MTD identified in the Phase I portion of the study will be used in the Phase II portion which will evaluate the efficacy, safety, and tolerability of neoadjuvant sunitinib/paclitaxel/carboplatin given for 6 cycles in patients with locally advanced breast cancer.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Drug: Paclitaxel
    IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
    Other Names:
    • Taxol
    • Systemic Therapy
  • Drug: Carboplatin
    IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
    Other Names:
    • Paraplatin
    • Systemic Therapy
  • Drug: Sunitinib
    By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
    Other Names:
    • Sutent
    • Systemic Therapy
Study Arms  ICMJE
  • Experimental: Dose Level I

    Neoadjuvant - Paclitaxel IV (70 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.

    Maintenance - Sunitinib PO (25mg) daily

    Interventions:
    • Drug: Paclitaxel
    • Drug: Carboplatin
    • Drug: Sunitinib
  • Experimental: Dose Level II
    Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
    Interventions:
    • Drug: Paclitaxel
    • Drug: Carboplatin
    • Drug: Sunitinib
  • Experimental: Dose Level III
    Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 6) day 1 of every cycle and Sunitinib PO (25mg) daily.
    Interventions:
    • Drug: Paclitaxel
    • Drug: Carboplatin
    • Drug: Sunitinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 9, 2014)
54
Original Estimated Enrollment  ICMJE
 (submitted: April 23, 2009)
53
Actual Study Completion Date  ICMJE September 2014
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Female patients, age ?18 years
  2. Histologically confirmed invasive ER-, PR-, and HER2-negative (triple-negative) adenocarcinoma of the breast
  3. Triple-negative tumors are defined as:

    • For HER2-negative:
    • Fluorescence in situ hybridization (FISH)-negative (defined by ratio <2.2) OR
    • Immunohistochemical (IHC) 0, IHC 1+, OR
    • IHC 2+ or IHC 3+ and FISH-negative (defined by ratio <2.2)
    • For ER- and PR-negative: <10% tumor staining by immunohistochemistry (IHC)
  4. Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). T1N0M0 lesions are excluded. Patients with metastatic disease are excluded.
  5. Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. Patients with lesions measurable only by imaging will require repeat imaging after 3 cycles and prior to surgery
  6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2
  7. Neuropathy grade <1 by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0)
  8. Resolution of all acute effects of surgical procedures to grade ?1.

    For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound is required

  9. Adequate hematologic function with:

    • Absolute neutrophil count (ANC) >1500/?L
    • Platelets ?100,000/?L
    • Hemoglobin ?10 g/dL
  10. Adequate hepatic and renal function with:

    • Serum bilirubin ? the institutional upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 x institutional ULN
    • Alkaline phosphatase ?2.5 x institutional ULN
    • Serum creatinine ?1.5 x ULN or calculated creatinine clearance ?40 mL/min
  11. Left ventricular ejection fraction (LVEF) ?50% by multigated acquisition (MUGA) or echocardiogram (ECHO)
  12. Bilateral, synchronous breast cancer is allowed if one primary tumor meets the inclusion criteria
  13. Knowledge of the investigational nature of the study and ability to provide consent for study participation
  14. Ability and willingness to comply with study visits, treatment, testing, and other study procedures

Exclusion Criteria:

  1. Previous treatment for this breast cancer
  2. Previous treatment with paclitaxel or carboplatin
  3. Previous treatment with sunitinib or other angiogenic inhibitors (including, but not limited to bevacizumab, sorafenib, thalidomide)
  4. Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolus
  5. Uncontrolled hypertension (blood pressure >150/100 mmHg despite optimal medical therapy)
  6. Ongoing cardiac dysrhythmias grade ?2, atrial fibrillation of any grade, or prolongation of the QTc interval to >470 msec
  7. Major surgery, significant traumatic injury, or radiation therapy within 4 weeks of starting study treatment. An interval of at least 1week is required following minor surgical procedures, with the exception of placement of a vascular access device
  8. Grade 3 hemorrhage within 4 weeks of starting study treatment
  9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
  10. Known human immunodeficiency virus (HIV) infection or other serious infection
  11. Concomitant treatment with drugs having proarrhythmic potential including terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, and flecainide
  12. Concurrent use of the potent CYP3A4 inhibitors ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine and voriconazole and CYP3A4 inducers rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's Wort, and dexamethasone. Use of dexamethasone for study premedication is allowed. Grapefruit and grapefruit juice is prohibited. Alternative therapies should be used when available. If use of a potent CYP3A4 inhibitor or inducer is necessary, this must be approved by the Study Chair
  13. Known or suspected hypersensitivity to drugs containing Cremophor®EL (polyoxyethylated castor oil) such as cyclosporine or teniposide
  14. Pregnancy or breast-feeding. Negative serum pregnancy test is required within 7 days prior to first study treatment (Day 1, Cycle ) for all women of childbearing potential. Patients of childbearing potential must agree to use a birth control method that is approved by their study physician while receiving study treatment and for three months after the last dose of study treatment. Patients must agree to not breast-feed while receiving study treatment
  15. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Patients must have discontinued use of such agents prior to beginning study treatment
  16. History of malignancy treated with curative intent within the previous 5 years with the exception of skin cancer, cervical carcinoma in situ, or follicular thyroid cancer. Patients with previous invasive cancers (including breast cancer) are eligible if the treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease
  17. Use of any investigational agent within 30 days of administration of the first dose of study drug or concurrent treatment on another clinical study
  18. Requirement for radiation therapy concurrent with study anticancer treatment. Patients who require breast or chest wall radiation therapy after surgery are eligible, but will have maintenance sunitinib interrupted while receiving radiation
  19. Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that would cause reasonable suspicion of a disease or condition, that contraindicates the use of study drugs, that may increase the risk associated with study participation, that may affect the interpretation of the results, or that would make the patient inappropriate for this study
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00887575
Other Study ID Numbers  ICMJE SCRI BRE 122
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party SCRI Development Innovations, LLC
Study Sponsor  ICMJE SCRI Development Innovations, LLC
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Denise A Yardley, M.D.SCRI Development Innovations, LLC
PRS Account SCRI Development Innovations, LLC
Verification Date September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP